Decoding 9 Analyst Evaluations For Axsome Therapeutics
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has been analyzed by 9 analysts in the last three months, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased to $129.89. Despite some positive ratings, the company faces financial challenges, including a decline in revenue and below-industry-average profitability metrics.
July 18, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Axsome Therapeutics has received mixed analyst ratings with an average 12-month price target increase to $129.89. Despite some positive ratings, the company faces significant financial challenges, including a 20.7% decline in revenue and below-industry-average profitability metrics.
The mixed analyst ratings and slight increase in the average price target suggest a neutral short-term impact on the stock price. However, the company's financial challenges, including declining revenue and low profitability, may offset any positive sentiment from the ratings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100